Maureen Hillenmeyer, Hexagon Bio CEO

Hexa­gon Bio rais­es $61M to con­tin­ue ef­forts to turn fun­gi in­to drugs

A year af­ter rais­ing a $47 mil­lion launch round, the fun­gi-lov­ing drug hunters at Hexa­gon Bio have more than dou­bled their cof­fers.

Hexa­gon an­nounced to­day that it raised an­oth­er $61 mil­lion for its ef­forts to de­sign can­cer and in­fec­tious dis­ease drugs based on in­sights mined from the DNA in mil­lions of species of fun­gi. The new fi­nanc­ing brings Hexa­gon’s com­mit­ted fund­ing to over $108 mil­lion.

Nex­tech In­vest led the fi­nanc­ing, along with new in­vestors Soft­Bank Vi­sion Fund 2 and Cas­din Cap­i­tal. The Col­umn Group, 8VC, and Two Sig­ma Ven­tures com­mit­ted funds as re­turn­ing in­vestors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.